Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.

Sonya AndersonLaura CotigualaSarah M Tischer Jeong Mi ParkKatie McMurry

Published in: The Annals of pharmacotherapy (2020)

Newer antidiabetic agents have been recommended by the American Diabetes Association for potential cardiovascular, renal, and hypoglycemic benefits. Particular agents, such as DPP-4 inhibitors and GLP-1 RAs may play a role in correcting PTDM-related defects. Clinicians need to take into account both patient-specific and drug-specific characteristics when initiating these agents in KTRs.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
emergency department
palliative care
human health
insulin resistance
drug induced
adverse drug
weight loss